GGrantIndex
← Search

Administrative Supplement to Cancer Center Support Grant to Support Acquisition and Annotation of Biospecimens

$46,200P30FY2018CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

The Karmanos Cancer Institute (KCI) is a charitable 501(c)(3) organization affiliated with Wayne State University (WSU) dedicated to cancer care, research, and education with the ultimate goal to eradicate this disease. Our catchment area includes the four-county area of Wayne, Oakland, Macomb, and Monroe, a population of 4.0 million. The demographic makeup of metropolitan Detroit, which in its entirety is within our catchment area, is 82.7% African American. The demographic makeup of our entire catchment area is 24.3% African American. The nearby city of Dearborn includes the largest concentration of Arabs outside the Middle Eastern countries. Challenges and opportunities facing both us and the City of Detroit include the economy (unemployment is 9.8%, 38.1% live below the poverty level) and education (47.0% of the adult population are functionally illiterate). Cancer rates in our catchment area generally outpace state and national rates. In calendar year 2013, KCI?s inpatient and ambulatory facilities (KCH) cared for a total of 6,013 new patients (2,420 registered cancer patients by NCI?s definition) with 29.4% representing minority groups. In the same year, our minority accrual to interventional treatment protocols was 27.4%. We have a long standing scientific and patient care commitment to the African American population of southeastern Michigan, as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This application profiles the strengths and successes of our four scientific Programs, Tumor Biology and Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population Studies and Disparities Research (PSDR, 04). Nine Shared Resources are proposed, one of which is a new Shared Resource. The Center?s total annual direct project funding is $56,240,646 (an increase of 5.1% over the 2010) of which $30,685,044 is peer reviewed funding. Of peer reviewed funding, $16,235,791 is from the NCI. Over the next grant period, KCI aims to substantially participate in our Nation?s efforts to: 1) Discover molecules, mechanisms, and pathways that contribute to the causes, progression, and evasion from therapeutic interventions of cancer with special attention to racial, ethnic, and socioeconomic factors as process modifiers; 2) Develop molecules, devices, models, tools, and approaches that lead to an effective reduction in cancer risk, tissue invasion, and metastatic spread, as well as enhancement of communication with and engagement of patients, their families and care providers, and communities at large; and 3) Deliver promising novel therapies and interventions to the population of Michigan through our distributed network of 18 cancer care delivery sites that cover 48 of the 83 counties of Michigan with special attention to racial and ethnic minorities, as well as socioeconomically disadvantaged groups.

View original record on NIH RePORTER →